Disease · MONDO_0005546
Comparisons in its trials50
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 50
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| DS-5565 15 mg QD Modal vs DS-5565 15 mg BID Modal: deaths from any cause | 3 of 847 | 2 of 1,241 | 2,088 | NCT02234583 | Trial comparisons |
| DS-5565 15 mg QD Modal vs DS-5565 15 mg BID Modal: serious adverse events | 41 of 847 | 94 of 1,241 | 2,088 | NCT02234583 | Trial comparisons |
| Milnacipran vs Placebo: serious adverse events | 10 of 516 | 7 of 509 | 1,025 | NCT00314249 | Trial comparisons |
| TNX-102 SL Tablet, 2.8 mg vs Placebo SL Tablet: Proportion of Patients With ≥30% Pain Improvement | 75 of 262 | 58 of 257 | 519 | NCT02436096 | Trial comparisons |
| TNX-102 SL Tablet, 2.8 mg vs Placebo SL Tablet: Patient's Global Impression of Change (PGIC) | 62 of 262 | 42 of 257 | 519 | NCT02436096 | Trial comparisons |
| TNX-102 SL Tablet, 2.8 mg vs Placebo SL Tablet: deaths from any cause | 0 of 262 | 0 of 256 | 518 | NCT02436096 | Trial comparisons |
| TNX-102 SL Tablet, 2.8 mg vs Placebo SL Tablet: serious adverse events | 3 of 262 | 4 of 256 | 518 | NCT02436096 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: deaths from any cause | 0 of 256 | 0 of 258 | 514 | NCT04508621 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: Number of Patients With a Patient's Global Impression of Change (PGIC) Rating of Very Much Improved or Much Improved | 76 of 256 | 56 of 258 | 514 | NCT04508621 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: serious adverse events | 6 of 256 | 0 of 258 | 514 | NCT04508621 | Trial comparisons |
| TNX-102 SL Tablets, 5.6 mg vs Placebo SL Tablet: deaths from any cause | 0 of 248 | 0 of 255 | 503 | NCT04172831 | Trial comparisons |
| TNX-102 SL Tablets, 5.6 mg vs Placebo SL Tablet: Number of Patients With a Patient's Global Impression of Change (PGIC) Rating of Very Much Improved or Much Improved | 93 of 248 | 75 of 255 | 503 | NCT04172831 | Trial comparisons |
| TNX-102 SL Tablets, 5.6 mg vs Placebo SL Tablet: serious adverse events | 2 of 248 | 5 of 255 | 503 | NCT04172831 | Trial comparisons |
| Pregabalin vs Placebo: serious adverse events | 1 of 250 | 0 of 248 | 498 | NCT00830167 | Trial comparisons |
| Pregabalin vs Placebo: Medical Outcomes Study (MOS) Sleep Scale - Number of Participants With Optimal Sleep at Endpoint | 71 of 249 | 53 of 247 | 496 | NCT00830167 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: deaths from any cause | 0 of 231 | 0 of 226 | 457 | NCT05273749 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: serious adverse events | 2 of 231 | 3 of 226 | 457 | NCT05273749 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: Proportion of Patients With a Patient's Global Impression of Change (PGIC) Rating of Very Much Improved or Much Improved at the Week 14 Endpoint | 66 of 231 | 34 of 225 | 456 | NCT05273749 | Trial comparisons |
| Duloxetine 60 mg vs Placebo: serious adverse events | 1 of 194 | 1 of 196 | 390 | NCT01552057 | Trial comparisons |
| TNX-TNX vs PBO-TNX: deaths from any cause | 0 of 177 | 0 of 198 | 375 | NCT02589275 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005546/comparisons